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as those of the Cancer Data Standards Registry and Repository (caDSR) 
need to be adopted more widely to ensure uniformity. For a given 
biomarker, a classification needs to include the type of marker 
(whether diagnostic, prognostic, predictive, or companion diagnostic), 
the marker’s characteristics (e.g. what it is measuring in terms of 
pathways, or receptor status, at the molecular level), the physiologic 
compartment source (e.g. blood, urine, tissue, CSF, bone marrow), 
and the setting including clinical presentation and scenario specificity 
(i.e. when the marker is useful and relevant).  For the latter the 
decision will also need to address whether new diseases (e.g. HPV-
driven cancer) should continue to be combined with the classic 
version of oropharyngeal cancer since emerging data has underlined 
the separate nature of these processes at the etiology, clinical, 
pathological, molecular, and outcome levels. This may also extend to 
whether the TNM classification should even be the same for both 
diseases. 
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In the near future rational individualisation of radiation dose 
prescription will be possible. Current technology now allows the 
distribution of radiation dose to be tightly controlled and advances in 
our understanding of the biology of the disease will lead to 
individualisation of radiation dose delivery both within individual 
patients and between different patients. 
Functional imaging is at the present time the most likely candidate 
technology to influence our choice of individualising the dose 
distribution, however a number of unanswered questions remain 
before this can become a reality.  
This presentation will review the current state of this area of research 
and discuss likely forward directions of research. Clinical trials to 
evaluate these technologies will be discussed.  
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Radiofrequency ablation for liver metastases 
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Radiofrequency ablation (RFA) is regarded as the primary ablative 
modality for local tumour destruction at most institutes.  It involves 
delivery of high-frequency, in the range of 375 to 500 kHz, alternating 
electrical current into the target tissue through a needle electrode.  
Electrical current passes back and forth through the body between the 
electrode and some grounding pads putting on the skin of the thighs.   
The high frequency of alternating current causes rapid movement of 
the ions or charged molecules within the cells in the tissue 
surrounding the electrode.  Heat is produced by friction during the 
rapid movement of these molecules. Temperature in excess of 50 °C 
produces coagulative necrosis.  A 2 to 5 cm spherical thermal injury 
can be produced with each ablation, depending on the design of the 
needle electrode. 
The main aim of thermal tumour ablation therapy is to destroy an 
entire tumour, with a 1 cm margin, in a minimally invasive fashion 
without damaging adjacent vital structures.  Each ablation requires 
exact placement of electrode in the tumour.  Any radiofrequency 
needle electrodes can be inserted percutaneously, under laparoscopic 
guidance or during laparotomy.  With percutaneous approach, the 
electrodes can be placed under sonographic, CT, or MR guidance.  
The major complications associated with RFA occur in 2.2–3.1% of 
patients. The minor complication rate ranges from 5% to 8.9%. 
Complications are divided into 3 different types: thermal damage 
(gastrointestinal perforation, biliary stenosis, cardiac tamponade and 
grounding pad burns), mechanical complications (injuries to bile ducts 
and vessels, tumour seeding and hemorrhage), and septic 
complications (abscess and peritonitis). Treatment of lesions adjacent 
(< 1 cm) to the hepatic hilum increases the risk of thermal injury of 
the major biliary tract and represents a relative contraindication to 
RFA. Thermal ablation of lesions adjacent to hepatic vessels increases 
the risk of incomplete treatment of the neoplastic tissue close to the 
vessel due to heat loss or heat sink effect. 
From the recent data on long-term survival of nonsurgical patients 
(due to comorbidity, patient refusal or unfavourable anatomy) with 
colorectal liver metastases (CRLM) who underwent RFA, the 5-year 
survival rate ranges 24–44%. These figures are substantially higher 
than those obtained with any chemotherapy regimens and provide 
indirect evidence that RFA therapy improves survival in patients with 
limited hepatic metastatic disease. 
Currently, liver resection (LR) is regarded as the gold standard 
treatment for resectable CRLM. One of the greatest criticisms for the 
utilization of RFA for treatment of CRLM has been a concern of high 
local recurrence at the RFA site. Local recurrence rates after RFA in 
the literature have been quite variable and range from 4% to 55%.  A 
recent meta-analysis found the overall local recurrence rate to be 
14.7%. 
Multiple studies have been published comparing RFA to LR for 
treatment of CRLM. In a recent published meta-analysis, 3-year  and 
5-year disease free survival as well as 3- year and 5-year overall 
survival are significantly higher in the LR group.  
Based on these retrospective reports, several authors have concluded 
that RFA is not equivalent to surgical resection and therefore should 
not be used to treat lesions that are otherwise resectable. Due to the 
retrospective nature of these studies, and the significant bias in 
patient selection, these results are difficult to interpret and the role 
of RFA remains biased. In addition, these retrospective studies are not 
randomized. 
The use of RFA does not prevent simultaneous or subsequent use of 
other, potentially complementary, treatments. Combining with other 
treatment modality is probably the future direction for RFA in the 
treatment of CRLM. 
There is limited data on the use of RFA in treating hepatic metastases 
from non CRLM.  The conclusion from those published 
studies employing RFA to treat non CRLM is that RFA is regarded as an 
adjunct to resection and unresectable lesions that demonstrate 
positive response after chemotherapy.   
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The present evidence for local ablation of liver oligo-metastases is 
limited. No randomized controlled trial has ever proven the efficacy 
of local ablation on survival, and the evidence is even poorer when it 
comes to comparisons of the different ablation methods. Surgical 
resection has by tradition been the preferred therapy for liver oligo-
metastases and radiofrequency ablation (RFA) is frequently used for 
treatment of inoperable patients. Stereotactic body radiation therapy 
(SBRT) is most often number three in line and has been used for 
therapy of medical inoperable patients and patients who are not 
amendable for surgery or RFA for technical reasons. These reasons are 
most often related to size of the metastases or the anatomical 
distribution in the liver. Where SBRT has been standard of care in 
therapy of patients with limited stage non-small cell cancer and 
lungmetastases for some time, the introduction of SBRT in the 
treatment of tumors in the liver has been characterized by hesitation.  
A number of retrospective and few prospective studies have been 
published on SBRT for liver metastases. In general, studies are 
characterized by considerably heterogeneity concerning patient 
selection. Retrospective studies often include a variety of tumor types 
with variability of number and size of the metastases and this 
translates into a broad variability in outcome. The most frequent 
tumor type investigated is colorectal carcinoma (CRC) metastases, but 
there are studies including almost all tumor types. Some studies show 
that survival outcomes are not different for CRC and non-CRC 
patients. Most studies demonstrate high local control rates ranging 80-
90% in SBRT for liver metastases. Treatment techniques, doses and 
fractionation varies between the studies, but an effect of dose 
escalation on the local control is fairly consistent. It is generally 
accepted that when using a 3 fraction schedule, the prescription dose 
should be at least 48 Gy.  
The morbidity after SBRT for liver metastases is mild to moderate. 
Most often it is limited to temporary abdominal wall pain, rib fracture 
and erythema. Severe morbidity related to exposure of the stomach or 
bowel and hepatic failure due to radiation hepatitis, a few being 
fatal, have been reported. 
Novel radiotherapy techniques have contributed to the improved 
precision in delivery of largeradiation doses to defined targets by 
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SBRT. Multimodal imaging for target definition, image guidance 
techniques utilizing implanted fiducial markers, 4D-CT scanning and 
respiration management techniques have considerable improved the 
SBRT.  
In general, the approach to metastatic disease has become more 
aggressive. A number of specialties offer therapies for patients with 
liver oligo-metastases and a multidisciplinary team approach in the 
management of these patients is of utmost importance. Radiotherapy 
may be utilized for a group of patients who cannot be treated by 
surgery or RFA and the radiation oncologist should therefore be a 
member of the team. 
There is sufficient data demonstration that SBRT can be used in 
therapy of liver metastases when the constraints to critical tissues 
such as stomach, bowel and lover are respected, but there is a great 
need for randomized clinical trials to prove the efficacy of SBRT in 
treatment of oligo-metastases and for trials to explore the need for 
systemic therapy along with SBRT. It is therefore strongly encouraged 
to participate in large multi-institutional randomized trials. 
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When a patient is diagnosed with liver metastases it is by definition a 
systemic disease and metastases at other sites should also be 
expected. This is also the case for the third most common cancer 
disease, colorectal cancer (CRC). Almost half of all patients with CRC 
will develop liver metastases (CLM) and approximately a fourth of 
them have only the liver as metastatic site. If the patient has no 
serious co-morbidities and 30 percent of the liver parenchyma and one 
hepatic vein can be saved there is indication for liver resection. This 
is a relative safe procedure with a postoperative mortality below five 
percent and this subpopulation of patients with CRC has a 5-year 
survival of 40-50 percent and 30 percent 10-year survival.  
The good outcome in liver resected patients is the main reason for 
follow-up with tumour markers and CT scan after surgery of the 
primary tumour. 
Neoadjuvant chemotherapy will slightly improve progression free 
survival but not overall survival. Still most patients are today offered 
neoadjuvant therapy. From a multidisciplinary perspective conversion 
therapy is important. A majority of patients with CLM will get a 
response on chemotherapy and they shall then be reconsidered for 
liver resection. The 5-year survival is as good as for patients who were 
primarily resectable. On the other hand, patients with CLM that 
progress on chemotherapy have a bad prognosis, even after liver 
resection.  
From a surgical point of view a patient might have a limited 
metastatic volume in the liver but one or more small metastases can 
be badly situated. In this case ablative techniques (radiofrequence or 
microwave ablation) or stereotactic radiotherapy can be of great 
value to complement resection of other parts of the liver. 
Even if CLM is the most common indication for liver resection of 
metastatic disease there are other cancer diseases where surgery for 
oligo-metastatic disease shall be considered. These are primarily 
neuroendocrine tumours (NET), renal cell cancer, melanoma and 
ovarian cancer. As with CLM there are no randomised studies to 
support the indication for surgery but the evidence are generated by 
comparing survival of liver resected patients with a cohort who had 
similar tumour burden but were not operated. 
 
 SYMPOSIUM: FUNCTIONAL IMAGING FOR RADIO-
THERAPY DOSE PAINTING  
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Quantitative MR imaging for radiotherapy  
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Quantitative MRI holds the promise to augment radiotherapy with 
functional imaging, which may enable improved tumor targeting, and 
more personalized treatment based on a priori characterization of 
imaging biomarkers and early assessment of treatment response.  This 
lecture emphasizes some factors of quality, validation, and 
applications of quantitative MRI metrics.  
Diffusion-weighted imaging (DWI) geometric accuracy at 3 Tesla:  
Geometric accuracy is of fundamental importance for incorporation of 
anatomic imaging into radiation therapy, yet the geometric accuracy 
of clinical DWI pulse sequences is under-emphasized.  Segmented 
echo-planar (EPI) DW imaging is an accessible solution on many pre-
clinical high-field MRI systems, providing dramatic geometric accuracy 
improvement compared to single-shot EPI-DWI at similar scan time 
and signal-to-noise.  Utilizing the RESOLVE works-in-progress package 
provided by Siemens Medical Systems, segmented EPI DWI has been 
investigated as an option for more geometrically accurate clinical DWI 
at 3T.  The geometric accuracy improvement from RESOLVE is verified 
using an in vitro prostate phantom, and applied in vivo to enable 
tumor-targeted radiation therapy treatment planning for prostate 
cancer at 3 Tesla based on DWI and T2-weighted image co-registration 
(see Figure). 
Dynamic contrast enhanced (DCE) MRI validation against DCE-CT:  
DCE-MRI has broad appeal as a clinical biomarker for radiation 
oncology, yet presents with known limitations to accuracy and 
precision.  These known limitations apply to both vessel-based 
measurements of arterial input function (AIF) and tumor-based 
measurements of permeability and perfusion.  Methodologic 
improvements have been incorporated at 3 Tesla and tested against 
the standard of DCE-CT.  First, a multi-modal DCE-MRI/CT flow 
phantom has been applied to investigate factors affecting AIFs 
measured using the MRI magnitude signal, and to validate AIFs 
measured using the MRI signal phase.  Second, a 4D temporal 
segmentation (TDS) method, which enables voxel-based, parametric 
analysis based on patient-specific dynamic behaviour of contrast flow, 
has been implemented to facilitate tissue-level analysis.  Preliminary 
testing has compared DCE-CT supported by 4D-TDS to standard DCE-
MRI analysis for the detection of early changes in brain tumor 
perfusion following radiosurgery. 
Stromal imaging:  Hedgehog (Hh) pathway inhibition is a potential 
strategy to overcome treatment resistance and repopulation in 
patients undergoing radiotherapy and concurrent chemotherapy, and 
it is now widely held that the Hh pathway promotes tumor growth 
indirectly through paracrine effects on the stroma.  MRI biomarkers to 
monitor Hh inhibition and stromal depletion have been investigated in 
murine models of human cervical, pancreatic, and breast cancer, 
utilizing the 7 Tesla MRI of the STTARR facility, with emphasis on DCE-
MRI, magnetization transfer, and DWI.   
Figure: A prostate DWI geometric distortion phantom, consisting of 
distilled water within concentric acrylic cylinders of 3, 6, and 12 cm 
(e.g. corresponding to the outer diameter of the Hologic endorectal 
coil diameter; the anterior peripheral zone; and the anterior prostate) 
was imaged with RESOLVE and standard DWI at 3 T (1.4x.1.4x3-mm 
resolution, 28 slices). (a, b) Meshes of cylinder boundaries for 
RESOLVE and standard DWI were generated, and cylinder boundaries 
were tracked to quantify vertical distortion in the phase encoding 
direction. Compared to standard DWI, RESOLVE reduced the mean RMS 
displacement of inner and middle cylinders 3-fold (to 0.5 mm) and 
reduced the maximum distortion in y from 13 to 3 mm. (c-d) clinical 
prostate RESOLVE and standard DWI ADC maps at 3T in matched 
slices, verifying distortion reduction in vivo in approximately 




   
 
 
 
